Haleon, a consumer healthcare firm, has announced an investment of £130 million ($169 million) to build an innovation centre in Weybridge, UK.
The new facility will reportedly feature state-of-the-art, digitally enabled research laboratories and a dedicated consumer behaviour research facility, employing 450 staff. This new facility intends to support Haleon’s oral health portfolio, including brands like Sensodyne, Polident/Poligrip, Aquafresh and Corsodyl.
Commenting on the move, Haleon CEO Brian McNamara said: “Our decision to locate our Global Oral Health Innovation Centre in Weybridge reflects our confidence in the UK as a great place for a global company like ours to thrive. This facility is central to our efforts to attract and retain the best talent to fuel our growth and the continuous innovation which is so vital for delivering better everyday health”.
The innovation centre, to be built on a 90,000 sq ft site, is expected to open in 2027.
Source: Haleon